Barbara Pistilli

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 532 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +13

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard et al. · Advances in Therapy · 2013 · 505 citations · Full text

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 318 citations · Full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study

Hatem A. Azim, Niels Kroman, Marianne Paesmans et al. · Journal of Clinical Oncology · 2012 · 245 citations · Full text